Article

Artist's Balancing Act Inspires New York's Hope Murals Project

New York artist and GIST survivor, Ellen Mayer, painted "Balancing Act" to describe how she felt about her cancer experience. The artwork was later selected as one of 10 pieces to be publicly painted for The Hope Murals Project.

New York artist and gastrointestinal stromal tumors survivor, Ellen Mayer, painted "Balancing Act" in 2010 to help describe how she felt about her cancer experience and survivorship, including the constant need to balance emotions that come with it.

"I felt like I was constantly balancing in my head: Is it going to come back, is it not going to come back? That’s what this represents," she says. "All these little people represent life, and everybody in life, whether it’s cancer or anything else you’re going through, there is a point where you have to say 'OK, this is what it is and this is how I’m going to get back to balance.'"

After submitting the piece in 2010 for the Lilly Oncology on Canvas art competition, the organizers called Mayer this year to let her know that her "Balancing Act" was selected to be a part of the 10th anniversary of the competition. Mayer's original piece was made into nine large interlocking pieces, which were painted individually by the public on Oct. 23 in New York's Grand Central Terminal as part of The Hope Murals Project.

[Oncology on Canvas and The Hope Murals Project Reaches New York City]

The Hope Murals Project allows anyone who has been impacted by cancer, including patients, survivors and caregivers, to help paint a series of 10 murals around the country.

Related Videos
Image of woman.
Dr. Andreas M. Kaiser is a professor and chief of the Division of Colorectal Surgery in the Department of Surgery at City of Hope comprehensive cancer center in Duarte, California.
Dr. Guru Sonpavde emphasized the importance of better understanding how genetic mutations influence the treatment of cancer care, particularly GU cancers.
Image of woman with blonde hair.
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Dr. Park sat down for an interview with CURE® to discuss the key takeaways from the 2025 Annual ASCO Genitourinary Cancers Symposium.
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
There was no evidence that CAR T directly caused secondary malignancies, despite FDA warnings, citing prior treatments as the cause, according to research.
Image of woman with black hair.
Image of man with black hair.